Perioperative medicine & outcomes
Mortality, morbidity, and impact on future anaesthesia after perioperative anaphylaxis related to neuromuscular blocking agents: an 11-year single-centre retrospective study
Authors' conclusion
This study highlighted a significant underestimation of the incidence of perioperative anaphylaxis related to neuromuscular blocking agents and reporting to the local and national pharmacovigilance centre despite allergy assessment. Morbidity occurred in 20% of patients, primarily involving renal and cardiovascular complications, with most patients making a full recovery.
Study context
- Population
- Adults receiving neuromuscular blocking agents (NMBAs) during GA at Lille University Hospital, France, 2012–2022, with grade II, III or IV NMBA-related anaphylaxis82 allergist-confirmed
- Participants
- 94 adults
- Outcome
- Outcomes (mortality, morbidity) and impact on future anaesthesia after NMBA-related perioperative anaphylaxis
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Incidence of perioperative anaphylaxis per 100 000 NMBA administrations, all agents (158 021 GA with NMBA)
- 58.1
- Death within 90 days
- 4
- Morbidity
- 19 (20%)
- Renal failure
- 12
- Cardiovascular complications
- 8
- Neurological complications
- 4
- Full recovery among patients with morbidity
- 12 of 19
- Subsequent anaesthetic procedures screened, surgery completed without NMBAs
- 96
Observational data: associations, not effects.
Further findings
Reporting to a pharmacovigilance centre
- Cases reported
- 14.9%
Original publication
Mortality, morbidity, and impact on future anaesthesia after perioperative anaphylaxis related to neuromuscular blocking agents: an 11-year single-centre retrospective study. Br J Anaesth. Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →